
NBP
Healthcare · Biotechnology · $98.6M market cap
$0.8499+0.02 (+2.4%)Nov 13, 4:00 PM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2026
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Sep 30, 2026 | Time not confirmed | -0.14 | -0.07 | +50.0% |
| Jun 25, 2026 | Time not confirmed | -0.12 | -0.04 | +66.7% |
| Dec 18, 2025 | Before the open | -0.05 | -0.06 | -20.0% |
| Aug 20, 2025 | Before the open | -0.12 | -0.07 | +41.7% |
| May 15, 2025 | Before the open | -0.07 | -0.04 | +42.9% |
| Nov 14, 2024 | Before the open | -0.07 | -0.11 | -57.1% |
| Aug 28, 2024 | Before the open | -0.22 | 0.30 | +236.4% |
| Nov 9, 2022 | After the close | -0.48 | -0.55 | -14.6% |
| Apr 28, 2022 | After the close | -0.51 | -0.70 | -37.3% |
| Nov 11, 2021 | After the close | -0.51 | -0.86 | -68.6% |
| Apr 28, 2021 | Before the open | 0.71 | 0.56 | -21.1% |
| Mar 29, 2021 | Time not confirmed | — | 2.19 | — |
| Dec 2, 2020 | Time not confirmed | — |
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment…
| 0.03 |
| — |
| Aug 31, 2020 | Before the open | -0.53 | -0.80 | -50.9% |